Table 5.
Reported impact of the COVID-19 variants mRNA-LNP vaccine efficacy and effectiveness.
| COVID-19 variant | Key mutations | Transmissibility | Vaccine-mediated protection | |
|---|---|---|---|---|
| BNT162b2 (Pfizer/BioNTech) | mRNA-1273 (Moderna Therapeutics) | |||
| Reference strain | Reference strain | Reference strain | 95% | 94.1% |
| Alpha (B.1.1.7) | ∆H69/V70, ∆Y144, N501Y, A570D, D614G, P681H | About 50% increase | 90% | 92% |
| Beta (B.1.351) | L18F, ∆L242, K417N, E484K, N501Y ,D614G, A701V | 25% increase | 75% | 89% |
| Gamma (P.1) | L18F, E484K, K417N/T, N501Y, D614G | 1.4 - 2.2 times more | 82% | 89% |
| Delta (B.1.617.2) | T95I, L452R, T478K, D614G, P681R | 97% increase | 88% (2 dose) | 91% (2 dose) |
| Omicron (B.1.1.529) | G339D, S373P, S375F, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H S371L, G446S, G496S (for BA.1) S371F, R408S (for BA.2) |
~ 3.2 times (for Delta) |
65.5% (2 dose) 67.2% (Booster) |
75.1% (2 dose) 64.9% (Booster) |
It may not be accurate due to the continuous updates in each country.